Market Access, Thursday 1 March 2018


Organiser's Welcome Remarks

Asia's Biotech Landscape:Innovation & Funding

Carolyn Ng

Venture capital funding for the biotech industry

It takes millions of dollars to transform an innovative idea to a commercially viable pharma product. Especially in developing countries where the government has other more important healthcare priorities, the role of the VC becomes even more crucial and necessary for early stage biotech company and its success. Find out how venture capitalists can tap on knowledge learnt from more established biotech ecosystem and apply these lessons in Asia. 
John Connolly

Fostering biotech and bio-entrepreneurship in Southeast Asia (SEA): How do we build the next biotech unicorn in SEA?

Southeast Asia is a geographically diverse region diverse lifestyles and traditions. The majority of SEA countries are still in developing stages and R&D intensive industries are not a priority compared to industries that rapidly close the income gap between the rich and the needy. Nonetheless, we are beginning to see a thriving biotech landscape offering innovative solutions. What needs to be done to help these promising companies fully realise their potential? How can the region come together to support the biotech industry, and build a biotech unicorn? 
Panel discussion

The Macro View: What will it take for Asia’s biotech industry to really flourish?

Everyone knows it is too generic to classify all Asian countries in a single category. With the exception of China and India, the remaining part of Asia is complicated, fragmented and diversified. With growing GDPs and middle class populations, the potential of Asia’s biotech industry is undeniable in the eye of global leaders. The main question is, how can government and related stakeholders assist the biotech industry to flourish to provide more affordable, personalised medicine for its populations? How do countries move away from a “me-too” to “me-first” mentality, especially when it comes to pharma R&D?
Tabassum Khan, Managing Director, AJ Pharma Holding

Speed Networking


Exhibition Visit & Networking Refreshments

Asia Partnering Framework

Yuliana Indriati
Market Access

Building the right ecosystem to support the new era of Indonesia biopharma industry

    style="font-size: 10.0pt;">
  •     Overview of innovation and investment made to promote pharma industry in Indonesia 
  •     Case study: Joint venture with Genexine to produce biobetter drugs in Indonesia.
  •     Insights learnt from drug development, clinical trials and manufacturing biologics in home grown facilities to support local, ASEAN and greater Asia population 
Lalit Baregama
Market Access

Case study: Strategic partnership for effective pharmaceutical development and manufacturing

Anushree Agarwal
Market Access

Case study: Practical steps to prepare for product launch in APAC and Greater China

Panel discussion
Market Access

Panel discussion: To partner or to launch? Strategies for exploring Asia’s emerging markets

  • Analysing commercial opportunities and in-country competition to formulate most the optimal access strategy
  • How do innovators compete with biosimilars to keep their market share of expiring biologics products? Is it about more than just price?
  • Case study

Roundtable Discussion Session

Now's your chance to get really interactive. Simply pick a table and join the debate. 

Table 1: Innovative platforms for small molecules and gene therapy drug development

Table 2: Avoiding delays in clinical manufacturing of drug product

Manufacturing issues were the primary reason given for non-approvals in many of the response letters issued by the FDA in 2016. These manufacturing issues not only delay drug development, but also complicate the relationship between drug firms and their contract manufacturers. We will discuss the common issues, including planning, risk management, selection of primary packaging & materials, contract documents, and guidelines for choosing the right partner that can offer the quality necessary for successful clinical manufacturing. A trustworthy CDMO supports you with realistic project timelines and a framework of high product quality, while you focus on your core competencies of discovery and clinical development.

Table 3: Launching new biologics production line

Table 4: Commercial strategies for digital health in Asia

Amkidit Afable, Director Go-to-Market Strategies, Johnson & Johnson

Table 5: Why don’t we have an ICI in breast cancer – yet?

Table 6: Working on a start-up setting, from clinical development to commercialisation

Table 7: AI& Big data in drug discovery

Table 8: Preparation steps to brace healthcare & pharma digital transformation


Exhibition Visit & Networking Lunch


Market Access

Chair's Opening Remarks

Christian Wards
Market Access

Value in healthcare: A payer’s perspective

    style="font-size: 10.0pt;">
  •     Overview of current healthcare and reimbursement system in Asia
  •     From a payer’s perspective, what needs to be done to tackle pricing trends, from reimbursed to out of pocket markets
  •     Case studies
Market Access

Promoting access to healthcare in developing countries

  •     Exploring the win-win pricing structure where payers, pharma and patients will be best benefitted
  •     Latest update in country, from pharma to biologics and orphan products
  •     Case studies
Bobby George
Market Access

Impact of India’s latest pharmaceutical policy on drug development, production, pricing and reimbursement

  •     Overview of latest regulatory landscape and how it affects domestic and international stakeholders
  •     Exploring opportunities and hurdles presented by the new policy
  •     Focusing on pricing & reimbursement: What does local and international pharma companies need to know to prepare for this change? 

Exhibition Visit & Networking Refreshments


Santosh Jha
Market Access

RWE Generation: The current realities and capabilities required in Medical Affairs

  • Identifying challenges and opportunities using Real world evidence in reimbursement propositions
  • Cross-country analysis in better planning for HEOR execution
  • Setting digital platforms to connect patients to cloud for more accurate information gathering
Chung-Lin Yang
Market Access

HTA in Taiwan: An update

    style="font-size: 10.0pt;">
  •     Introduction of ahealthcare framework in Taiwan, including the role of CDE and National Health Insurance (NHI) in reimbursement decision
  •     Understanding the role of HTA in Taiwan reimbursement evaluation process
  •     Best practices to ensure neutrality in evaluation process, including roles of drug providers and patients in evaluation processes  
Market Access

Technology assessment for new oncology drug

    evelopment of targeted therapies and personalised cancer drugs offers opportunities, but also increases the complexity of the assessment. In this session, we will examine :
  •     Strategies for the assessment of new treatments, including possible join assessment
  •     Best practice for translating trial efficacy into effective clinical practice

Networking Cocktail & Phar-East Industry Awards Presentation

last published: 14/Feb/18 03:55